|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
11 Biopolis Way, #12-07/08 Helios, Singapore, SG
|
|
Invitrocue is a leading healthcare bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
Invitrocue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com
|
Invitrocue Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Invitrocue email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Invitrocue customer service number in your country click here to find.
Steven Fang is the CEO of Invitrocue. To contact Steven Fang email at [email protected] or [email protected]. Or you may call +65.62950080, +61423279585, +6597398883 or +6568190001
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.